Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. [electronic resource]
Producer: 20190705Description: 8 p. digitalISSN:- 1741-7015
- Adult
- Aged
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Cardiotoxicity -- epidemiology
- Chemotherapy, Adjuvant -- adverse effects
- Doxorubicin -- administration & dosage
- Female
- Humans
- Middle Aged
- Neoadjuvant Therapy -- adverse effects
- Paclitaxel -- administration & dosage
- Polyethylene Glycols -- administration & dosage
- Receptor, ErbB-2
- Trastuzumab -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.